NASDAQ : IBRX

ImmunityBio, Inc.

$7.1 USD

-$0.3 (-4.05%)

Volume
8.5M
Average Volume
12.89M
Market Capitalization
$7.44B
P/E Ratio
-8.32
Dividend Yield
0.00%
Price Target
$12.00
Year High
$12.43
Year Low
$1.95
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$6.67
Company Overview

NASDAQ

Richard Gerald Adcock

Biotechnology

Healthcare

IBRX

691

US

USD

https://immunitybio.com

858 633 0300

45256X103

0001326110

Liquidity Metrics

-1.29

6.67

6.66

3.02

0.00

Sales & Valuation

$113.29M

52.75

-8.38

-24.84

-0.29

Profitability

-$0.38

-$351.4M

-606.15%

-606.13%

138.69%

-132.15%

P/E Metrics

-8.32

0.06

0.06

Analyst Price Target & Rating

$12.00

$15.00

$12.00

Sell

2/5

5 Analysts

-40.83%

Financial Health Scores

-9.35

3/9

$385M

$646.64M

$1.52B

-$742.37M

Key Metrics (TTM)

$8.36B

59.27

-11.50

6.67

138.69%

-44.51%

-11.72%

-4.03%

-332 days

Company Executives
Name Title
Patrick Soon-Shiong FRCS Founder, Executive Chairman and Global Chief Scientific & Medical Officer
Enrique Diloné Chief Technology Officer
Leonard S. Sender Chief Medical Officer of Liquid Tumors & Cell Therapy
Sandeep K. Reddy Chief Medical Officer
Regan J. Lauer Chief Accounting Officer
Sarah Singleton Chief Communications Officer & Head of Patient Advocacy
David C. Sachs Chief Financial Officer
Barry J. Simon Chief Corporation Affairs Officer & Director
Richard Gerald Adcock President, Chief Executive Officer & Director
Emily Arison Senior Vice President of Human Resources
Poll Results

No votes yet today — be the first to share your view!

About ImmunityBio, Inc. (NASDAQ:IBRX) Stock

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various ... liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.

ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)

2026-07-20 08:30:25

ImmunityBio earns a cautious buy rating as Anktiva demonstrates strong efficacy and safety in NMIBC and shows promise across broader oncology indications. IBRX's valuation now reflects significant future revenue; rapid share appreciation and anticipated dilution temper near-term upside despite robust revenue ramp and pipeline catalysts. Anktiva's combination with BCG outperforms competitors, with 84% CR in BCG-naïve NMIBC and potential label expansion pending FDA decision in early 2027.

ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy

2026-07-17 12:09:33

ImmunityBio offers a best-in-class, approved immunotherapy, ANKTIVA, driving rapid revenue growth and significant market share in NMIBC. IBRX's pipeline is robust, with multiple Phase 1-3 trials targeting NSCLC, glioblastoma, HIV, and other high-value indications, supporting long-term upside. The recent 40% pullback from 52-week highs creates an attractive entry point, with strong balance sheet support and no immediate financial risks.

Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now

2026-07-13 14:29:04

Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearish bets have gone all‑in, turning these stocks into live‑wire squeeze candidates rather than sleepy laggards.

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

2026-07-10 12:04:38

Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.

ImmunityBio: A Long-Term Bull Case Worth Watching

2026-07-07 04:07:39

ImmunityBio is pivoting from a single-product Anktiva focus to a broad immunotherapy platform, emphasizing memory-like cytokine-enriched NK cells (M-ceNK). Key near-term catalysts include the pivotal QUILT-2.005 bladder cancer trial, lymphopenia indication expansion, and the glioblastoma (GBM) program, each validating the immune-restoration thesis. IBRX trades at a significant premium (65x trailing sales, 44x forward sales), reflecting high expectations for Anktiva's transition to first-line therapies and broader platform validation.

ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?

2026-06-29 09:01:15

ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

2026-06-01 14:00:00

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

2026-06-01 13:51:00

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirect comparison (MAIC) in BCG unresponsive non-muscle invasive bladder cancer (NMIBC), and collectively e.

Frequently Asked Questions

What is the current ImmunityBio, Inc. (IBRX) stock price?

ImmunityBio, Inc.(NASDAQ:IBRX) stock price is $7.1 in the last trading session. During the trading session, IBRX stock reached the peak price of $12.43 while $1.95 was the lowest point it dropped to. The percentage change in IBRX stock occurred in the recent session was --4.05% while the dollar amount for the price change in IBRX stock was -$0.3.

IBRX's industry and sector of operation?

The NASDAQ listed IBRX is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of IBRX?

Patrick Soon-Shiong FRCS | Founder, Executive Chairman and Global Chief Scientific & Medical Officer
Enrique Diloné | Chief Technology Officer
Leonard S. Sender | Chief Medical Officer of Liquid Tumors & Cell Therapy
Sandeep K. Reddy | Chief Medical Officer
Regan J. Lauer | Chief Accounting Officer

How many employees does IBRX have?

Number of IBRX employees currently stands at 691. IBRX operates from 3530 John Hopkins Court, San Diego, CA 92121, US.

Link for IBRX official website?

Official Website of IBRX is: https://immunitybio.com

How do I contact IBRX?

IBRX could be contacted at phone #858 633 0300 and can also be accessed through its website. IBRX operates from 3530 John Hopkins Court, San Diego, CA 92121, US.

How many shares of IBRX are traded daily?

The average number of IBRX shares traded daily for last 3 months was 12.89M.

What is the market cap of IBRX currently?

The market value of IBRX currently stands at $7.44B with its latest stock price at $7.1